Ready 8-Ks
26
Latest filing
May 18, 2026, 5:15 PM ET
Top materiality
0.85
Event mix
earnings ×9 · leadership ×6 · other_material ×4
Sentiment
5 pos · 7 neg · 14 neu
Latest earnings
reported 2026-Q1
-
Acadia subsidiary faces $105M jury verdict in retaliatory termination suit
San Diego jury awarded $35M compensatory and $70M punitive damages on May 12, 2026.
-
Acadia Healthcare Q1 revenue up 7.6% to $828.8M; raises FY2026 guidance
Revenue $828.8M (+7.6% YoY); same-facility revenue +7.3%.
-
Acadia Healthcare CFO Todd Young departs; former CFO David Duckworth returns as Interim CFO; guidance reaffirmed
Todd Young resigns as CFO effective April 30, 2026; to join private equity-backed animal health company.
-
Acadia Healthcare Q4 net loss $13.02/sh on $996M goodwill impairment; appoints new CEO
Q4 revenue $821.5M (+6.1% YoY); net loss $13.02/diluted share from $996.2M goodwill impairment.
-
CEO Christopher H. Hunter departs Acadia Healthcare effective Jan 20, 2026; separation agreement disclosed
CEO Christopher H. Hunter resigned and left Board effective Jan 20, 2026; no successor named.
-
Acadia Healthcare appoints former CEO Debra Osteen as CEO; Chris Hunter departs
Debra Osteen appointed CEO and Class I director effective January 20, 2026; previously served as CEO from 2018-2022.
-
Acadia Healthcare lowers 2025 guidance after actuarial review shows $49M PLGL expense increase
Adjusted EBITDA guidance reduced to $601-611M from $650-660M; adjusted EPS to $1.94-2.04 from $2.35-2.45.
-
Acadia Healthcare settles securities class action for $179M; no admission of liability
Settlement of $179M resolves St. Clair County ER Sys. v. Acadia Healthcare case with no admission of liability.
-
Acadia Q3 revenue $851.6M (+4.4% YoY), net income falls; cuts full-year guidance; COO resigns
Q3 net income $36.2M ($0.40 diluted) vs $0.74 prior year; adjusted EPS $0.72 vs $0.91.
-
Acadia Healthcare 2026 capex to drop at least $300M; Q3 same-facility patient days up 1.3%
Total 2026 capex expected to decline at least $300M from 2025 guidance of $600-$650M.
-
Acadia Q2 revenue $869M (+9.2%), adjusted EPS $0.83; CFO Dixon resigns, Sides interim
Q2 revenue $869.2M (+9.2% YoY); same-facility revenue +9.5% with 7.5% higher rev/patient day.
-
Acadia Healthcare Q1 revenue $770.5M, net income $8.4M, affirms FY2025 guidance
Revenue $770.5M, up 0.3% YoY from $768.1M; same-facility revenue +2.1%, patient days +2.2%.
-
Acadia Healthcare prices $550M 7.375% senior notes due 2033 to repay revolver
Issued $550M aggregate principal of 7.375% Senior Notes due March 15, 2033.
-
Acadia Healthcare enters $1.65B senior secured credit facility, extends maturities to 2030
New $1B revolver and $650M term loan, both due Feb 28, 2030; replaces $600M revolver and term loan due Mar 2026.
-
Acadia Healthcare Q4 2024 revenue $774.2M (+4.2%); adj. EPS $0.64; announces $300M buyback
Q4 net income $32.6M ($0.35 diluted EPS); adjusted income $59.2M ($0.64 diluted EPS).
-
Acadia Q3 revenue $815.6M (+8.7%), adj. EPS $0.91; margins expand
Revenue $815.6M, up 8.7% YoY; adjusted EBITDA $194.3M, up 10.5% YoY (excl. provider relief funds).
-
Acadia Healthcare receives federal subpoenas over admissions, billing practices
Voluntary request from US Attorney's Office (SDNY) and grand jury subpoena from Western District of Missouri.
-
Acadia Healthcare Q2 revenue up 8.8% to $796M; adj. EPS $0.91 provides updated 2024 guidance
Revenue $796.0M (+8.8% YoY); same-facility revenue +8.3% (patient days +2.6%, revenue/patient day +5.6%).
-
Acadia Healthcare Q1 revenue up 9.1% to $768.1M, adjusted EBITDA up 14.9%, affirms FY2024 guidance
Revenue $768.1M (+9.1% YoY); same-facility revenue +9.2%; net income $76.4M ($0.83 diluted EPS).